Integrated Filing (Finance) Ind AS


Anglo-French Drugs & Industries Limited

General Information
BSE Scrip code 000000
NSE Symbol*NOTLISTED
MSEI Symbol *AFDIL
ISIN*INE570E01016
Type of companySME
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved12-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange29-01-2026
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterThird quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year endedUnaudited
Segment ReportingMulti segment
Description of single segment
Start date of board meeting12-02-2026
Start time of board meeting12:30:00
End date of board meeting12-02-2026
End time of board meeting14:30:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?false
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?true

Amount in (Lakhs)

Financial Results - Ind-AS
Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations2,004.006,728.00
Other income401.004,736.00
Total income2,405.0011,464.00
2Expenses
(a)Cost of materials consumed397.001,264.00
(b)Purchases of stock-in-trade1,271.003,428.00
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade22.00580.00
(d)Employee benefit expense380.001,168.00
(e)Finance costs44.00150.00
(f)Depreciation, depletion and amortisation expense91.00248.00
(g)Other Expenses
1Rebates and Discount allowed3.0049.12
2Factory Power and Fuel34.00105.18
3Legal & Professional Fee31.60107.87
4Office and General Expenses66.37134.43
5Investment Expenses14.1838.00
6Rent36.5056.67
7Repair & Maintenance30.2592.33
8Tour & Travelling Expenses72.00184.00
9Vehicle Running & Maintenance19.0086.40
10Other Expenses39.10217.00
Total other expenses346.001,071.00
Total expenses2,507.007,909.00
3Total profit before exceptional items and tax102.003,555.00
4Exceptional items0.00174.00
5Total profit before tax102.003,381.00
6Tax expense
7Current tax0.000.00
8Deferred tax0.000.00
9Total tax expenses0.000.00
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement0.000.00
11Net Profit Loss for the period from continuing operations102.003,381.00
12Profit (loss) from discontinued operations before tax0.000.00
13Tax expense of discontinued operations0.000.00
14Net profit (loss) from discontinued operation after tax0.000.00
15Share of profit (loss) of associates and joint ventures accounted for using equity method0.000.00
16Total profit (loss) for period102.003,381.00
17Other comprehensive income net of taxes4.007.00
18Total Comprehensive Income for the period98.003,388.00
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital113.00113.00
Face value of equity share capital1010
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations-9299
Diluted earnings (loss) per share from continuing operations-9299
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations-9299
Diluted earnings (loss) per share from continuing and discontinued operations-9299
24Debt equity ratio0.00%0.00%
25Debt service coverage ratio0.00%0.00%
26Interest service coverage ratio0.00%0.00%
27Remarks for debt equity ratio
28Remarks for debt service coverage ratio
29Remarks for interest service coverage ratio
30Disclosure of notes on financial results

Amount in (Lakhs)

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
1Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1Pharmaceuticals2,004.006,728.00
2Investments377.004,631.00
Total Segment Revenue2,381.0011,359.00
Less: Inter segment revenue0.000.00
Revenue from operations2,381.0011,359.00
2Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1Pharmaceuticals339.00865.00
2Investments217.004,148.00
Total Profit before tax122.003,283.00
i. Finance cost0.000.00
ii. Other Unallocable Expenditure net off Unallocable income24.00105.00
Profit before tax98.003,388.00
3(Segment Asset - Segment Liabilities)
Segment Asset
1Pharmaceuticals14,032.0014,032.00
2Investments14,040.0014,040.00
Total Segment Assets28,072.0028,072.00
Un-allocable Assets0.000.00
Net Segment Assets28,072.0028,072.00
4Segment Liabilities
Segment Liabilities
1Pharmaceuticals12,220.0012,220.00
2Investments4.004.00
Total Segment Liabilities12,224.0012,224.00
Un-allocable Liabilities0.000.00
Net Segment Liabilities12,224.0012,224.00
Disclosure of notes on segments

Amount in (Lakhs)

Other Comprehensive Income
Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
No records available
Total Amount of items that will not be reclassified to profit and loss
2Income tax relating to items that will not be reclassified to profit or loss4.007.00
3Amount of items that will be reclassified to profit and loss
No records available
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss0.000.00
5Total Other comprehensive income

Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Sr. No.Details of the party (listed entity /subsidiary) entering into the transactionDetails of the counterpartyType of related party transactionDetails of other related party transactionValue of the related party transaction as approved by the audit committeeRemarks on approval by audit committeeValue of the related party transaction ratified by the audit committeeDate of Audit Committee Meeting where the ratification was approvedValue of transaction during the reporting periodIn case monies are due to either party as a result of the transactionIn case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investmentsDetails of the loans, inter-corporate deposits, advances or investments
NameNameRelationship of the counterparty with the listed entity or its subsidiaryOpening balanceClosing balanceNature of indebtedness (loan/ issuance of debt/ any other etc.)Details of other indebtednessCostTenureNature (loan/ advance/ intercorporate deposit/ investment)Interest Rate (%)TenureSecured/ unsecuredPurpose for which the funds will be utilised by the ultimate recipient of funds (endusage)Notes
No records available

Amount in (Lakhs)

Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr.ParticularsAmountRemarks
1.Loans / revolving facilities like cash credit from banks / financial institutions
ATotal amount outstanding as on date0.00
BOf the total amount outstanding, amount of default as on date0.00
2.Unlisted debt securities i.e. NCDs and NCRPS
ATotal amount outstanding as on date0.00
BOf the total amount outstanding, amount of default as on date0.00
3.Total financial indebtedness of the listed entity including short - term and long - term debt0.00